FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306160743> ?p ?o ?g. }

• W4306160743 abstract "Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. This study presents detailed immunological evidence to clarify the requirements for one- or two-dose primary vaccination series for naturally primed individuals. The main objective was to evaluate the immune response to COVID-19 mRNA vaccination to establish the most appropriate vaccination regimen to induce robust immune responses in individuals with prior SARS-CoV-2 infection. The main outcome measure was a functional immunity score (zero to three) before and after vaccination, based on anti-RBD IgG levels, serum capacity to neutralize live virus and IFN-γ secretion capacity in response to SARS-CoV-2 peptide pools. One point was attributed for each of these three functional assays with response above the positivity threshold. The immunity score was compared based on subjects' symptoms at diagnosis and/or serostatus prior to vaccination. None of the naïve participants (n=14) showed a maximal immunity score of three following one dose of vaccine compared to 84% of the previously infected participants (n=55). All recovered individuals who did not have an immunity score of three were seronegative prior to vaccination, and 67% had not reported symptoms resulting from their initial infection. Following one dose of vaccine, their immune responses were comparable to naïve individuals, with significantly weaker responses than individuals who were symptomatic during infection. These results indicate that the absence of symptoms during initial infection and negative serostatus prior to vaccination predict the strength of immune responses to COVID-19 mRNA vaccine. Altogether, these findings highlight the importance of administering the complete two-dose primary regimen and following boosters of mRNA vaccines to individuals who experienced asymptomatic SARS-CoV-2 infection." @default.
• W4306160743 created "2022-10-14" @default.
• W4306160743 creator A5000732151 @default.
• W4306160743 creator A5005935743 @default.
• W4306160743 creator A5006489308 @default.
• W4306160743 creator A5008649323 @default.
• W4306160743 creator A5024078113 @default.
• W4306160743 creator A5026563943 @default.
• W4306160743 creator A5031394685 @default.
• W4306160743 creator A5033873670 @default.
• W4306160743 creator A5036928197 @default.
• W4306160743 creator A5037475587 @default.
• W4306160743 creator A5044355614 @default.
• W4306160743 creator A5047643301 @default.
• W4306160743 creator A5050818906 @default.
• W4306160743 creator A5053223966 @default.
• W4306160743 creator A5064405479 @default.
• W4306160743 creator A5075968145 @default.
• W4306160743 creator A5087776685 @default.
• W4306160743 date "2022-10-14" @default.
• W4306160743 modified "2023-10-12" @default.
• W4306160743 title "Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine" @default.
• W4306160743 cites W1994162940 @default.
• W4306160743 cites W2074423750 @default.
• W4306160743 cites W2256756668 @default.
• W4306160743 cites W3001118548 @default.
• W4306160743 cites W3003668884 @default.
• W4306160743 cites W3011488280 @default.
• W4306160743 cites W3016269138 @default.
• W4306160743 cites W3025320502 @default.
• W4306160743 cites W3025631553 @default.
• W4306160743 cites W3084879098 @default.
• W4306160743 cites W3093667122 @default.
• W4306160743 cites W3108193091 @default.
• W4306160743 cites W3121008609 @default.
• W4306160743 cites W3124144456 @default.
• W4306160743 cites W3125525522 @default.
• W4306160743 cites W3127288595 @default.
• W4306160743 cites W3132054000 @default.
• W4306160743 cites W3133819496 @default.
• W4306160743 cites W3134757598 @default.
• W4306160743 cites W3136570200 @default.
• W4306160743 cites W3146894320 @default.
• W4306160743 cites W3155262144 @default.
• W4306160743 cites W3159185240 @default.
• W4306160743 cites W3159733845 @default.
• W4306160743 cites W3172271359 @default.
• W4306160743 cites W3178772652 @default.
• W4306160743 cites W3180511106 @default.
• W4306160743 cites W3190606158 @default.
• W4306160743 cites W3190702764 @default.
• W4306160743 cites W3206717788 @default.
• W4306160743 cites W4200122134 @default.
• W4306160743 cites W4200186202 @default.
• W4306160743 cites W4205240144 @default.
• W4306160743 cites W4205486034 @default.
• W4306160743 cites W4206040938 @default.
• W4306160743 cites W4206069935 @default.
• W4306160743 cites W4207082385 @default.
• W4306160743 cites W4210654369 @default.
• W4306160743 cites W4210708247 @default.
• W4306160743 cites W4210915576 @default.
• W4306160743 cites W4210930529 @default.
• W4306160743 cites W4220907252 @default.
• W4306160743 cites W4225795841 @default.
• W4306160743 cites W4225854071 @default.
• W4306160743 cites W4229053936 @default.
• W4306160743 cites W4288069250 @default.
• W4306160743 cites W4296686923 @default.
• W4306160743 doi "https://doi.org/10.3389/fimmu.2022.930252" @default.
• W4306160743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36311736" @default.
• W4306160743 hasPublicationYear "2022" @default.
• W4306160743 type Work @default.
• W4306160743 citedByCount "2" @default.
• W4306160743 countsByYear W43061607432023 @default.
• W4306160743 crossrefType "journal-article" @default.
• W4306160743 hasAuthorship W4306160743A5000732151 @default.
• W4306160743 hasAuthorship W4306160743A5005935743 @default.
• W4306160743 hasAuthorship W4306160743A5006489308 @default.
• W4306160743 hasAuthorship W4306160743A5008649323 @default.
• W4306160743 hasAuthorship W4306160743A5024078113 @default.
• W4306160743 hasAuthorship W4306160743A5026563943 @default.
• W4306160743 hasAuthorship W4306160743A5031394685 @default.
• W4306160743 hasAuthorship W4306160743A5033873670 @default.
• W4306160743 hasAuthorship W4306160743A5036928197 @default.
• W4306160743 hasAuthorship W4306160743A5037475587 @default.
• W4306160743 hasAuthorship W4306160743A5044355614 @default.
• W4306160743 hasAuthorship W4306160743A5047643301 @default.
• W4306160743 hasAuthorship W4306160743A5050818906 @default.
• W4306160743 hasAuthorship W4306160743A5053223966 @default.
• W4306160743 hasAuthorship W4306160743A5064405479 @default.
• W4306160743 hasAuthorship W4306160743A5075968145 @default.
• W4306160743 hasAuthorship W4306160743A5087776685 @default.
• W4306160743 hasBestOaLocation W43061607431 @default.
• W4306160743 hasConcept C126322002 @default.
• W4306160743 hasConcept C142462285 @default.
• W4306160743 hasConcept C203014093 @default.
• W4306160743 hasConcept C22070199 @default.
• W4306160743 hasConcept C2522874641 @default.
• W4306160743 hasConcept C2776535787 @default.

• next